clinical trial · NCT07503587
Evaluating the Efficacy and Safety of of HSK44459 in People With Progressive Pulmonary Fibrosis
Haisco Pharmaceutical Group Co., Ltd.·phase3·not yet recruiting·n = 378
Progressive Pulmonary FibrosisHSK44459Placebo
brief summary
This study is open to adults with PPF . The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
started
Apr 5, 2026
primary completion
Dec 30, 2028
completion
Mar 1, 2029
last updated
Mar 31, 2026
official title
A Randomised, Double-blind, Placebo-controlled Parallel Group Phase III Clinical Study Evaluating the Efficacy and Safety of HSK44459 Tablets in Subjects With Progressive Pulmonary Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol